SCHEMBL23927099

SCHEMBL23927099

C=CCN1C[C@@H]2C[C@H](O)CN(C(=O)OC(C)(C)C)[C@@H]2C1=O

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.36
POLB P06746 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C19 P33261 1/20 0.36
NR1H2 P55055 1/20 0.34
CHRM2 P08172 1/20 0.34
CHRM1 P11229 1/20 0.34
CHRM3 P20309 1/20 0.34
TGM2 P21980 2/20 0.34
F13A1 P00488 1/20 0.34
TGM1 P22735 1/20 0.34
AR P10275 1/20 0.33
HSD11B1 P28845 1/20 0.32
RIPK1 Q13546 1/20 0.31
KDM4E B2RXH2 1/20 0.30
JAK2 O60674 1/20 0.30
JAK1 P23458 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19990696 0.84
SCHEMBL28695065 0.84 NR1H2 (0.39) CYP1A2POLBCYP3A4CYP2C19NR1H2
SCHEMBL23927102 0.78 CYP1A2 (0.34) CYP1A2POLBCYP3A4CYP2C19NR1H2
SCHEMBL19865492 0.72 CHRM2 (0.47) CYP1A2POLBCYP3A4CYP2C19NR1H2
SCHEMBL20713877 0.72 CHRM2 (0.47) CYP1A2POLBCYP3A4CYP2C19NR1H2
SCHEMBL3971244 0.71 CYP1A2 (0.42) CYP1A2POLBCYP3A4CYP2C19NR1H2
SCHEMBL1267927 0.71 CYP1A2 (0.42) CYP1A2POLBCYP3A4CYP2C19NR1H2
SCHEMBL12836636 0.71 CYP1A2 (0.42) CYP1A2POLBCYP3A4CYP2C19NR1H2
SCHEMBL1268152 0.71 CYP1A2 (0.42) CYP1A2POLBCYP3A4CYP2C19NR1H2
SCHEMBL178642 0.71 CYP1A2 (0.42) CYP1A2POLBCYP3A4CYP2C19NR1H2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109843894-B Beta-lactamase inhibitors 诺华股份有限公司 2022-02-08 CN disclosed
EP-3698796-B1 PHARMACEUTICAL COMBINATION OF A TRICYCLIC BETA-LACTAMASE INHIBITOR WITH SPECIFIC BETA-LACTAM ANTIBIOTICS NOVARTIS AG (CH) 2021-10-27 EP disclosed